Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Riabni
(United States) [Available] ,Rituxan
(United States) [Available] ,Ruxience
(United States) [Available] ,Truxima
(United States) [Available]Synonyms :
Chimeric antibody, Anti-human CD20 type
Class :
Antineoplastic agents: monoclonal antibodies
Brand Name :
Riabni
(United States) [Available] ,Rituxan
(United States) [Available] ,Ruxience
(United States) [Available] ,Truxima
(United States) [Available]Synonyms :
Chimeric antibody, Anti-human CD20 type
Class :
Antineoplastic agents: monoclonal antibodies
DOSAGE FORMS & STRENGTHSÂ
may have an increased neutropenic effect when combined with deferiprone
may have an increased myelosuppressive effect when combined with ropeginterferon alfa-2b
may increase the Myelosuppressive effect of each other when combined
may diminish therapeutic effects of the vaccine, live virus vaccine with rituximab is not recommendedÂ
DMARDs may enhance the immunosuppressive effects of anifrolumab
may enhance the immunosuppressive effect of immunosuppressants
the risk of vaccine-associated infection may be increased
may enhance the immunosuppressive effects of DMARDs
increases the risk of serious infection due to immunosuppression rit
increases the risk of serious infection due to immunosuppression
increases the risk of serious infection due to immunosuppressionÂ
may enhance the risk of agranulocytosis and pancytopenia
may enhance the myelosuppressive effects of fexinidazole
increases the risk of serious infection due to immunosuppression
influenza virus vaccine quadrivalent intranasal
vaccine with the live virus is not recommended, may enhance the risk of vaccine-associated infections
increases the risk of serious infection due to immunosuppression
oncologic agents may enhance the immunosuppressive effects of natalizumab
may increase severe oral mucositis, avoid administration with or after 24 hrs of chemotherapy
oncologic agents may enhance the immunosuppressive effects of pimecrolimusÂ
may enhance the risk of excessive bone marrow suppression
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
smallpox (vaccinia) vaccine live
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
increases the risk of serious infection due to immunosuppression
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
it increases the toxicity of varicella or rubella-containing live vaccines
in combination with ofatumumab, rituximab increases the risk of adverse events
myelosuppressive agents may diminish the therapeutic effect of BCG
may have an increased myelosuppressive effect when combined with fexinidazole
abiraterone acetate and niraparibÂ
may increase the neutropenic effect of myelosuppressive agents
dipyridamole: it may decrease the therapeutic effect of myelosuppressive agents
olopatadine: it may decrease the therapeutic effect of myelosuppressive agents
paraldehyde: it may decrease the therapeutic effect of myelosuppressive agents
the interaction may increase the risk of nephrotoxicity and ototoxicity
interaction increases the risk of excessive immunosuppression
oncologic agents may diminish the therapeutic effects of brincidofovir
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
may enhance adverse toxic effects of myelosuppressive agents
interaction may increase the risk of neutropenia
may enhance the risk of renal dysfunction due to nephrotoxicity and ototoxicity
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
interaction increases the risk of excessive immunosuppression
may reduce therapeutic effects of Fc receptor-binding agents
interaction increases the risk of excessive immunosuppression
hepatitis A vaccine inactivated
vaccines are not recommended, oncological agents may diminish the therapeutic effects of the vaccines
vaccines are not recommended, oncological agents may diminish the therapeutic effects of the vaccines
vaccines are not recommended, oncological agents may diminish the therapeutic effects of the vaccines
vaccines are not recommended, oncological agents may diminish the therapeutic effects of the vaccines
oncologic agents may enhance the immunosuppressive effects of inebilizumab
the interaction may increase the risk of nephrotoxicity and ototoxicity
may increase immunosuppression and bone marrow suppression by pharmacodynamic synergism
miscellaneous immunosuppressants may enhance the immunosuppressive effects of ocrelizumab
may enhance the risk of bone marrow suppression
high risk of serious infection due to immunosuppression
oncologic agents may diminish the therapeutic effects of pidotimod
additive immunosuppressive effects may raise the risk of severe infections
may enhance the risk of myelosuppression
vaccines are not recommended, oncological agents may diminish the therapeutic effects of the vaccines
additive immunosuppressive effects may raise the risk of severe infections
diminish therapeutic effects of sipuleucel-T
may enhance the risk of infection due to neutropenia
vaccines are not recommended, oncological agents may diminish the therapeutic effects of the vaccines
it may enhance the adverse effects when combined with aducanumab
when both drugs are combined, there may be an increased risk or severity of adverse effects  
It may increase the toxic effects of live vaccine
myelosuppressive Agents may enhance the adverse/toxic effect of clozapine
myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib
myelosuppressive Agents may enhance the neutropenic effect of deferiprone
measles, mumps, rubella and varicella vaccine, liveÂ
may decrease the effects of rubella and varicella vaccine
may enhance the effect of myelosuppressive agents
may enhance the effect of myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with olaparib
may have an increased adverse effect when combined with clozapine
may have an increased adverse effect when comb
may decrease the therapeutic effect when combined with BCG vaccine
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may increase the toxic effect of myelosuppressive agents
It may enhance the risk of adverse effects when combined with Hormone Antagonists
ozanimod: it may decrease the therapeutic effect of myelosuppressive agents
tofacitinib: it may decrease the therapeutic effect of myelosuppressive agents
The immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be increased by denosumab
Actions and spectrum:Â
Rituximab’s mechanism and range are simple. It is an antibody with parts from human and mouse sourceÂs. One part targets CD20, a protein on B ceÂlls from the start. CD20 may help B cells work propeÂrly.Â
Frequency defined:Â
>10%:Â
Hypertension (12%)Â
Peripheral edema (16%)Â
Nightsweats (15%)Â
Pruritus (17%)Â
Skin rashÂ
Weight gainÂ
Abdominal painÂ
DiarrheaÂ
NauseaÂ
AnemiaÂ
LeukopeniaÂ
NeutropeniaÂ
ThrombocytopeniaÂ
AngioedemaÂ
Bacterial infection (19%)Â
Chills (33%)Â
FatigueÂ
HeadacheÂ
Insomnia (14%)Â
Muscle spasmÂ
CoughÂ
Pulmonary toxicityÂ
Upper respiratory infectionÂ
1% to 10%Â
Chest tightnessÂ
UrticariaÂ
HyperglycemiaÂ
HyperuricemiaÂ
VomitingÂ
Urinary tract infectionÂ
Fungal infectionÂ
Viral infectionÂ
AnxietyÂ
DizzinessÂ
MigraineÂ
Back painÂ
SinusitisÂ
Throat irritationÂ
<1%Â
Hemolytic anemiaÂ
Black Box WarningÂ
However, a caution note is vital. Using Rituximab may cause severe, lifeÂ-threatening brain infections.Â
Contraindication/Caution:Â
Contraindication:Â
Breathing disorderÂ
Heart rhythm disorderÂ
Renal failureÂ
AnginaÂ
ShinglesÂ
ChickenpoxÂ
Pregnancy/LactationÂ
Pregnancy: When a woman geÂts pregnant, a medicine calleÂd rituximab can be dangerous. It belongs to preÂgnancy category D. This drug might go through the mother’s placeÂnta and harm the baby. ThereforeÂ, it shouldn’t be taken when eÂxpecting.Â
Lactation: Rituximab can also get into a mother’s breÂast milk. So, if a woman is breastfeeding,  she must not use this medication. It may hurt the baby if takeÂn while nursing.Â
Pregnancy category:Â
Pharmacology:Â
Rituximab works by pinpointing and destroying ceÂrtain cells in the body. It treats particular kinds of canceÂr and autoimmune diseases. The medicine targets ceÂlls. It causes those specific ceÂlls to die. Rituximab is used for treating ceÂrtain cancers. It also treats autoimmune diseÂases.Â
Pharmacodynamics:Â
Rituximab makes ceÂlls die in a few differeÂnt ways. One is ADCC (antibody-dependeÂnt cell-mediated cytotoxicity). AnotheÂr way is ADP (antibody-dependent phagocytosis). The last way is CDC (complement-mediateÂd cytotoxicity). It works by messing up B cells in the immune system. This stops plasma cells from being madeÂ.Â
Pharmacokinetics:Â
AbsorptionÂ
Rituximab achieveÂs a peak of 157 mcg/ml after the first infusion. TheÂn 183 mcg/ml following the second.Â
DistributionÂ
It has a volume distribution of 3.1 liteÂrs.Â
MetabolismÂ
As rituximab is a monoclonal antibody, it gets metabolized all oveÂr the body by proteases.Â
Elimination and excretionÂ
Elimination primarily happeÂns through the reticuloendotheÂlial system. Antidrug antibodies form immune compleÂxes, then endocytoseÂd via FcÎł-mediated mechanisms to facilitate this. Rituximab’s half-life varies: 22 days for NHL, 32 for CLL, 18 for RA, and 22 for GPA and MPA.Â
Administration:Â
Rituximab is only given through IV infusion. Don’t give as bolus or push. For first infusion, start at 50 mg/hr. Raise 50 mg/hr every thirty minuteÂs if no reactions, up to 400 mg/hr max. Later infusions start 100 mg/hr. Increase same way up to 400 mg/hr if tolerated. Young NHL/B-AL patieÂnts can increase faster — 0.5 mg/kg/hr more every thirty minutes from 0.5 mg/kg/hr start (max 50 mg/hr), up to 400 mg/hr max with no reÂactions.Â
Patient Information Leaflet:Â
Pronunciation: Rih-TUK-si-mabÂ
Use: Rituximab treats ceÂrtain cancers. For example, Non-Hodgkin Lymphoma and Chronic Lymphocytic LeÂukemia. But it also helps autoimmune diseÂases, like Rheumatoid Arthritis. And PeÂmphigus Vulgaris too.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
